GlassScriptPhysician profile
Julia Ellen Garza
NPI 1235796616
$4,611.41
in general payments reported to CMS, 2019-2025
35 companies · $2,409 in 2025
The $2,409 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $76.12 · 2023: $102 · 2024: $2,024 · 2025: $2,409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,535.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $996.14 | 2024-2025 | Apretude, Cabenuva, Rukobia |
| Gilead Sciences, INC. | $708.05 | 2024-2025 | Yeztugo, Descovy, Biktarvy |
| Lilly USA, LLC | $307.13 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $265.33 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $243.98 | 2022-2025 | |
| Pfizer INC. | $209.03 | 2024-2025 | |
| Napo Pharmaceuticals INC | $197.24 | 2024-2025 | Mytesi |
| Theratechnologies INC. | $160.39 | 2024-2025 | Egrifta, Trogarzo |
| Antares Pharma, INC. | $157.67 | 2024-2025 | Xyosted |
| Takeda Pharmaceuticals U.S.A., INC. | $125.97 | 2024-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.21 | 2022-2025 | Xifaxan |
| Sumitomo Pharma America, INC. | $102.92 | 2024-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $81.67 | 2024-2025 | Pifeltro, Delstrigo |
| Janssen Pharmaceuticals, INC | $77.62 | 2024-2025 | Spravato, Xarelto |
| Emd Serono, INC. | $70.44 | 2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $70.01 | 2024-2025 | Cologuard Collection Kit |
| Almatica Pharma LLC | $69.27 | 2024-2025 | Loreev Xr |
| Astrazeneca Pharmaceuticals LP | $68.49 | 2024-2025 | Farxiga, Airsupra |
| Sanofi-Aventis U.S. LLC | $60.74 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.02 | 2024-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.28 | 2024-2025 | Jardiance, Tradjenta |
| Amgen INC. | $48.80 | 2024-2025 | Repatha, Otezla, Otezla |
| Abbott Laboratories | $46.51 | 2025 | Freestyle Libre 3 |
| Lundbeck LLC | $46.23 | 2024 | Rexulti |
| Axsome Therapeutics, INC. | $41.61 | 2025 | Symbravo, Auvelity |
| Tris Pharma INC | $36.93 | 2024 | Dyanavel Xr |
| Paratek Pharmaceuticals, INC. | $36.23 | 2024 | Nuzyra |
| Electromed, INC. | $23.01 | 2024 | Smartvest |
| Supernus Pharmaceuticals, INC. | $22.46 | 2025 | Qelbree |
| Novartis Pharmaceuticals Corporation | $22.40 | 2024 | |
| Phathom Pharmaceuticals, INC. | $19.34 | 2025 | Voquezna |
| Azurity Pharmaceuticals, INC. | $17.00 | 2025 | Azmiro |
| Dexcom, INC. | $16.91 | 2022 | |
| Hologic Sales and Service, LLC | $15.54 | 2024 | Aptima, Thinprep 2000 Processor, Third Wave |
| Aimmune Therapeutics, INC. | $14.84 | 2025 | Zenpep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Garza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.